At DoNotAge Conference 2026, Lindsay Bottoms and Jonathan Sinclair presented quercetin research focused on blood pressure and cardiometabolic health, alongside a separately registered UCLan trial that lists DoNotAge.org as a collaborator.
What was presented at the conference
The official DoNotAge Conference 2026 highlights present a 20-day quercetin study in healthy participants in which blood pressure fell by about 7 mmHg, followed by plans for further work in people with prehypertension or stage 1 hypertension.
That numerical result should be read as conference-stage evidence unless and until the underlying dataset is matched to a final paper or formal results record. It should not be silently imported into a different registered trial.
The registered UCLan study
ClinicalTrials.gov lists NCT06230861, “Effects of Quercetin Supplementation on Cardiometabolic Parameters,” sponsored by the University of Central Lancashire. Jonathan Sinclair is the responsible party, and DoNotAge.org is listed as a collaborator.
The registry describes an estimated 40-participant randomized, parallel, double-masked study comparing quercetin with placebo. Systolic blood pressure is a primary outcome, with additional measures including diastolic blood pressure, body composition, glucose, triglycerides, cholesterol, wellbeing and sleep-related questionnaires.
Current evidence state
The ClinicalTrials.gov record lists the study as recruiting and shows no posted results. A trial registry establishes what investigators plan to test; it does not establish that the intervention works.
The conference-stage 7 mmHg result and NCT06230861 should therefore remain distinct until a publication or official results record demonstrates that they are the same dataset.
The DoNotAge relationship
The registry’s role labels matter: the University of Central Lancashire is the sponsor, while DoNotAge.org is a collaborator. That is a documented research relationship, but it is not equivalent to DoNotAge sponsoring or independently running the study.
Sources
Official DoNotAge Conference 2026 highlights
ClinicalTrials.gov — NCT06230861
University of Hertfordshire — Lindsay Bottoms profile
Open the DoNotAge research tracker.
Linked entities and research
DoNotAge Conference 2026
DoNotAge Conference 2026 was held in London on September 26–27, 2026. The official highlights archive presents 12 2026 conversations spanning human trials, DNA repair, inflammation, muscle and exercise, replication and research funding, plus a 2025 conference recap.
Quercetin, Blood Pressure and the Human Trial
The official conference archive reports that 40 healthy adults joined a 20-day Pure Quercetin versus placebo trial and 38 completed it. It reports about a seven-point improvement in systolic blood pressure versus placebo, with improvements in triglycerides and self-reported sleep while other measured outcomes did not change significantly.
Effects of Quercetin Supplementation on Cardiometabolic Parameters — NCT06230861
ClinicalTrials.gov lists DoNotAge.org as a collaborator; the University of Central Lancashire is the sponsor.
Lindsay Bottoms
DoNotAge Conference 2026 speaker and co-presenter of the conference-reported 20-day Pure Quercetin versus placebo study. The related registered study NCT06230861 lists DoNotAge.org as a collaborator.
Jonathan Sinclair
Speaker at DoNotAge Conference 2026; responsible party for ClinicalTrials.gov study NCT06230861, which lists DoNotAge.org as a collaborator.